Literature DB >> 19596931

Discrepancies in expression and prognostic value of tumor markers in adenocarcinoma and squamous cell carcinoma in cervical cancer.

Annika K Lindström1, Tibor Tot, Ulf Stendahl, Stina Syrjänen, Kari Syrjänen, Dan Hellberg.   

Abstract

The expression of 11 tumor markers in 129 women with squamous cell compared to 31 women with adenomatous cervical cancer was investigated to detect differences in expression. There was a significantly higher expression of p53, CD4, epidermal growth factor receptor (EGFR), CD44 and stratifin in squamous cell, compared to adenocarcinoma, while there was a higher expression of c-myc in adenocarcinoma. P-53, cyclooxygenase-2 (Cox-2) and c-myc significantly correlated to prognosis in squamous cell carcinoma, but none of the 11 investigated tumor markers had any prognostic value in adenocarcinomas. The prognostic value of individual tumor markers differs with the histological subtype in cervical cancer.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19596931

Source DB:  PubMed          Journal:  Anticancer Res        ISSN： 0250-7005            Impact factor:   2.480


  8 in total

1.  Mutation analysis of EGFR and its correlation with the HPV in Indian cervical cancer patients.

Authors:  Rehana Qureshi; Himanshu Arora; Shilpi Biswas; Ahmad Perwez; Afreen Naseem; Saima Wajid; Gauri Gandhi; Moshahid Alam Rizvi
Journal:  Tumour Biol       Date:  2016-01-14

2.  Molecular characterization of c-Abl/c-Src kinase inhibitors targeted against murine tumour progenitor cells that express stem cell markers.

Authors:  Thomas Kruewel; Silvia Schenone; Marco Radi; Giovanni Maga; Astrid Rohrbeck; Maurizio Botta; Juergen Borlak
Journal:  PLoS One       Date:  2010-11-30       Impact factor: 3.240

3.  Evaluating the number of stages in development of squamous cell and adenocarcinomas across cancer sites using human population-based cancer modeling.

Authors:  Julia Kravchenko; Igor Akushevich; Amy P Abernethy; H Kim Lyerly
Journal:  PLoS One       Date:  2012-05-22       Impact factor: 3.240

4.  Hypoxia and TGF-β1 induced PLOD2 expression improve the migration and invasion of cervical cancer cells by promoting epithelial-to-mesenchymal transition (EMT) and focal adhesion formation.

Authors:  Feifei Xu; Jialu Zhang; Guolin Hu; Lei Liu; Weijiang Liang
Journal:  Cancer Cell Int       Date:  2017-05-12       Impact factor: 5.722

5.  Immunohistochemical LRIG3 expression in cervical intraepithelial neoplasia and invasive squamous cell cervical cancer: association with expression of tumor markers, hormones, high-risk HPV-infection, smoking and patient outcome.

Authors:  A K Lindström; D Hellberg
Journal:  Eur J Histochem       Date:  2014-04-15       Impact factor: 3.188

6.  Expression of cyclooxygenase-2 in cervical cancer is associated with lymphovascular invasion.

Authors:  Friederike Hoellen; Annika Waldmann; Constanze Banz-Jansen; Achim Rody; Maria Heide; Frank Köster; Julika Ribbat-Idel; Christoph Thorns; Maximilian Gebhard; Martina Oberländer; Jens K Habermann; Marc Thill
Journal:  Oncol Lett       Date:  2016-07-29       Impact factor: 2.967

7.  Prognostic significance of the co-expression of EGFR and HER2 in adenocarcinoma of the uterine cervix.

Authors:  Asako Ueda; Akira Takasawa; Taishi Akimoto; Kumi Takasawa; Tomoyuki Aoyama; Yoshihiko Ino; Masanori Nojima; Yusuke Ono; Masaki Murata; Makoto Osanai; Tadashi Hasegawa; Tsuyoshi Saito; Norimasa Sawada
Journal:  PLoS One       Date:  2017-08-31       Impact factor: 3.240

8.  Enlightening discriminative network functional modules behind Principal Component Analysis separation in differential-omic science studies.

Authors:  Sara Ciucci; Yan Ge; Claudio Durán; Alessandra Palladini; Víctor Jiménez-Jiménez; Luisa María Martínez-Sánchez; Yuting Wang; Susanne Sales; Andrej Shevchenko; Steven W Poser; Maik Herbig; Oliver Otto; Andreas Androutsellis-Theotokis; Jochen Guck; Mathias J Gerl; Carlo Vittorio Cannistraci
Journal:  Sci Rep       Date:  2017-03-13       Impact factor: 4.379
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.